Literature DB >> 29739896

Quantitative Proteomics Analysis of Sporadic Medullary Thyroid Cancer Reveals FN1 as a Potential Novel Candidate Prognostic Biomarker.

Shaohua Zhan1,2, Jinming Li2, Tianxiao Wang3, Wei Ge4.   

Abstract

BACKGROUND: Sporadic medullary thyroid cancer (MTC) is a rare neuroendocrine tumor. Currently, although the diagnosis of sporadic MTC is relatively simple, the need to discover novel candidate prognostic biomarkers for sporadic MTC and investigate the underlying mechanism involved in this rare disease is urgent.
MATERIALS AND METHODS: We employed tandem mass tag-based liquid chromatography-mass spectrometry to identify and analyze differentially expressed proteins (DEPs) in sporadic MTC. Western blotting was used to validate the DEPs. Immunohistochemistry was performed to investigate FN1 and RPS6KA3 in an independent set of sporadic MTC tissues. Immunohistochemical data were analyzed by different statistical methods.
RESULTS: Three hundred eighty-eight DEPs were identified in mass spectrometry, mainly involved in the extracellular matrix, cytoskeletal remodeling, or oxidoreductase activity. Among them, THBS1, MMP9, FN1, RPS6KA3, SYT1, and carcinoembryonic antigen were successfully validated by Western blot. In addition, FN1 and RPS6KA3, enriched in extracellular matrix (ECM) remodeling and the mitogen-activated protein kinase (MAPK) signaling pathway, respectively, were investigated in an independent set of sporadic MTC tissues. Receiver-operator characteristic curve analysis showed that FN1 and RPS6KA3 can be used for discriminating sporadic MTC tumorous tissues from paired normal thyroid tissues, and the clinical biomarker calcitonin was positively correlated with FN1 and RPS6KA3 in tumorous tissues. Furthermore, the immunohistochemical scores of FN1 in tumorous tissue showed an inverse relationship with tumor classification, lymph node classification, and American Joint Committee on Cancer stage. Through univariate and multivariate analysis for progression-free survival, we also found that low FN1 expression in tumorous tissues was an independent worse prognostic factor for progression-free survival.
CONCLUSION: We identified that the pathophysiology of sporadic MTC involve numerous pathways, including the synaptic vesicle pathway, the MAPK signaling pathway, and the ECM remodeling pathway. Furthermore, our study also identified FN1 as novel prognostic biomarkers related to the pathophysiologic changes in sporadic MTC. IMPLICATIONS FOR PRACTICE: Proteomic dissection and prognostic biomarkers are scarce in sporadic medullary thyroid cancer (MTC). This article reports the use of proteomics technology to comprehensively investigate the molecular mechanisms of sporadic MTC, which resulted in the identification of FN1 as a novel candidate prognostic biomarker. © AlphaMed Press 2018.

Entities:  

Keywords:  FN1; Quantitative proteomics; RPS6KA3; Sporadic medullary thyroid cancer; Tandem mass tag

Mesh:

Substances:

Year:  2018        PMID: 29739896      PMCID: PMC6292558          DOI: 10.1634/theoncologist.2017-0399

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  46 in total

1.  RET fusion as a novel driver of medullary thyroid carcinoma.

Authors:  Elizabeth G Grubbs; Patrick Kwok-Shing Ng; Jacquelin Bui; Naifa L Busaidy; Ken Chen; Jeffrey E Lee; Xinyan Lu; Hengyu Lu; Funda Meric-Bernstam; Gordon B Mills; Gary Palmer; Nancy D Perrier; Kenneth L Scott; Kenna R Shaw; Steven G Waguespack; Michelle D Williams; Roman Yelensky; Gilbert J Cote
Journal:  J Clin Endocrinol Metab       Date:  2014-12-29       Impact factor: 5.958

2.  Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases.

Authors:  Sanziana Roman; Rong Lin; Julie Ann Sosa
Journal:  Cancer       Date:  2006-11-01       Impact factor: 6.860

Review 3.  Characteristics and Significance of the Pre-metastatic Niche.

Authors:  Yang Liu; Xuetao Cao
Journal:  Cancer Cell       Date:  2016-11-14       Impact factor: 31.743

4.  Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases.

Authors:  F Puglisi; D Cesselli; G Damante; L Pellizzari; C A Beltrami; C Di Loreto
Journal:  Anticancer Res       Date:  2000 Jan-Feb       Impact factor: 2.480

Review 5.  RAS proto-oncogene in medullary thyroid carcinoma.

Authors:  Margarida M Moura; Branca M Cavaco; Valeriano Leite
Journal:  Endocr Relat Cancer       Date:  2015-10       Impact factor: 5.678

6.  Differential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions.

Authors:  Agnieszka Maliszewska; Luis J Leandro-Garcia; Esmeralda Castelblanco; Anna Macià; Aguirre de Cubas; Gonzalo Goméz-López; Lucía Inglada-Pérez; Cristina Álvarez-Escolá; Leticia De la Vega; Rocío Letón; Álvaro Gómez-Graña; Iñigo Landa; Alberto Cascón; Cristina Rodríguez-Antona; Salud Borrego; Mariangela Zane; Francesca Schiavi; Isabella Merante-Boschin; Maria R Pelizzo; David G Pisano; Giuseppe Opocher; Xavier Matias-Guiu; Mario Encinas; Mercedes Robledo
Journal:  Am J Pathol       Date:  2012-11-28       Impact factor: 4.307

7.  Expression profiles provide insights into early malignant potential and skeletal abnormalities in multiple endocrine neoplasia type 2B syndrome tumors.

Authors:  Sanjay Jain; Mark A Watson; Mary K DeBenedetti; Yuji Hiraki; Jeffrey F Moley; Jeffrey Milbrandt
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

8.  Analysis of Amyloid in Medullary Thyroid Carcinoma by Mass Spectrometry-Based Proteomic Analysis.

Authors:  Lori A Erickson; Julie A Vrana; Jason Theis; Michael Rivera; Ricardo V Lloyd; Ellen McPhail; Jun Zhang
Journal:  Endocr Pathol       Date:  2015-12       Impact factor: 3.943

Review 9.  Medullary thyroid cancer: management guidelines of the American Thyroid Association.

Authors:  Richard T Kloos; Charis Eng; Douglas B Evans; Gary L Francis; Robert F Gagel; Hossein Gharib; Jeffrey F Moley; Furio Pacini; Matthew D Ringel; Martin Schlumberger; Samuel A Wells
Journal:  Thyroid       Date:  2009-06       Impact factor: 6.568

10.  WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013.

Authors:  Jing Wang; Dexter Duncan; Zhiao Shi; Bing Zhang
Journal:  Nucleic Acids Res       Date:  2013-05-23       Impact factor: 16.971

View more
  17 in total

1.  The Overexpression of Fibronectin 1 Promotes Cancer Progression and Associated with M2 Macrophages Polarization in Head and Neck Squamous Cell Carcinoma Patients.

Authors:  Wan-Hang Zhou; Wei-Dong Du; Yan-Fei Li; Maged Ali Al-Aroomi; Cong Yan; Yao Wang; Ze-Ying Zhang; Fa-Yu Liu; Chang-Fu Sun
Journal:  Int J Gen Med       Date:  2022-05-17

2.  Asporin Interacts With HER2 to Promote Thyroid Cancer Metastasis via the MAPK/EMT Signaling Pathway.

Authors:  Shaohua Zhan; Tianxiao Wang; Jingying Li; Hanyang Zhu; Wei Ge; Jinming Li
Journal:  Front Oncol       Date:  2022-05-02       Impact factor: 5.738

3.  Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry.

Authors:  Dandan Li; Jie Wu; Zhongjuan Liu; Ling Qiu; Yimin Zhang
Journal:  PeerJ       Date:  2020-07-06       Impact factor: 2.984

4.  MetaOmGraph: a workbench for interactive exploratory data analysis of large expression datasets.

Authors:  Urminder Singh; Manhoi Hur; Karin Dorman; Eve Syrkin Wurtele
Journal:  Nucleic Acids Res       Date:  2020-02-28       Impact factor: 16.971

5.  Identification of the EMT-Related Genes Signature for Predicting Occurrence and Progression in Thyroid Cancer.

Authors:  Qiang Li; Sheng Jiang; Tienan Feng; Tengteng Zhu; Biyun Qian
Journal:  Onco Targets Ther       Date:  2021-05-12       Impact factor: 4.147

6.  Identifying hub genes of papillary thyroid carcinoma in the TCGA and GEO database using bioinformatics analysis.

Authors:  Ying Wan; Xiaolian Zhang; Huilin Leng; Weihua Yin; Wenxing Zeng; Congling Zhang
Journal:  PeerJ       Date:  2020-07-09       Impact factor: 2.984

7.  Genome-wide identification and analysis of A-to-I RNA editing events in the malignantly transformed cell lines from bronchial epithelial cell line induced by α-particles radiation.

Authors:  Qiaowei Liu; Hao Li; Lukuan You; Tao Li; Lingling Li; Pingkun Zhou; Xiaochen Bo; Hebing Chen; Xiaohua Chen; Yi Hu
Journal:  PLoS One       Date:  2019-06-03       Impact factor: 3.240

8.  Translational Metabolomics: Current Challenges and Future Opportunities.

Authors:  Farhana R Pinu; Seyed Ali Goldansaz; Jacob Jaine
Journal:  Metabolites       Date:  2019-06-06

9.  Identification of Serum miRNA-423-5p Expression Signature in Somatotroph Adenomas.

Authors:  Sida Zhao; Jianhua Li; Jie Feng; Zhenye Li; Qian Liu; Peng Lv; Fei Wang; Hua Gao; Yazhuo Zhang
Journal:  Int J Endocrinol       Date:  2019-07-17       Impact factor: 3.257

10.  In silico analysis of the immune microenvironment in bladder cancer.

Authors:  Ye Zhang; De-Hua Ou; Dong-Wu Zhuang; Ze-Feng Zheng; Ming-En Lin
Journal:  BMC Cancer       Date:  2020-03-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.